Mizuho analyst Anthony Petrone lowered the firm’s price target on Adma Biologics (ADMA) to $20 from $24 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics price target lowered to $18 from $21 at Canaccord
- Adma Biologics options imply 12.3% move in share price post-earnings
- Adma Biologics reports Q1 EPS 19c, consensus 20c
- Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M
- Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns